Home
Categories
Ingredients
Analysis
Manufacturing
Finance
Regulatory
Drug Delivery
Research & Development
Sustainability
Company News
Events
Directory
Search
Close search
Home
Company
GW Pharmaceuticals
GW Pharmaceuticals
Activities:
Ingredients
Research & Development
X
LinkedIn
Trending Articles
Neopac showcases latest tube, dispensing and cap innovations at Pharmapack Paris
Highlights include company’s reduced material LowPro caps and world’s smallest child resistant tube
Catalent and AstraZeneca to expand support for COVID-19 vaccine AZD1222
Catalent will prepare the Harmans facility, close to Baltimore-Washington International (BWI) airport, to enable multiple production trains to run in parallel to produce the...
Indian government bans three medicines owing to health risks
Decision follows strong stand on suspending marketing of all drugs prohibited for sale in other countries, including the US, UK, EU and Australia
You need to be a subscriber to read this article.
Click here
to find out more.
Parenteral preparations: formulation challenges
Parenteral preparations are defined as solutions, suspensions, emulsions for injection or infusion, powders for injection or infusion, gels for injection and implants. They are...
Lonza’s capsule delivers acid-sensitive ingredients to the intestine
The capsule can simplify the manufacturing process to accelerate drug development and expedite first-in-human timelines
Upcoming event
BioProcess International Europe
9-12 April 2024 | Exhibition | RAI Amsterdam
See all
Related Content
Finance
GW Pharmaceuticals reports Epidiolex sales of $296 million in first year
The British biopharmaceutical company has released Q4 and 2019 financial year results
Regulatory
GW Pharmaceuticals gains product recognition by NHS England
Epidyolex (cannabidiol) oral solution and Sativex (nabiximols) have been recommended for use by the UK’s National Institute for Health and Care Excellence
Manufacturing
Momentum in the US cannabidiol market gains retailers' attention
Walmart and other big-name stores in talks with food and drinks makers in preparation for the day CBD-enriched products are allowed on the shelves
Regulatory
First prescription CBD from GW Pharma has restriction lowered
The US Drug Enforcement Administration’s decision to move Epidiolex to Schedule V was based on non-clinical and clinical data that evaluated the medicine’s potential for abuse
Regulatory
First plant-derived cannabinoid prescription gains FDA approval
GW Pharmaceuticals has announced FDA approval of EPIDIOLEX (cannabidiol) oral solution, a medication prescribed for seizures associated with Lennox-Gastaut Syndrome or Dravet Syndrome
GW Pharmaceuticals receives orphan drug designation for cannabidiol
The European Medicines Agency granted the designation based on findings from the physician-led cannabidiol expanded access programme
Research & Development
GW Pharmaceuticals announces appointments to Board of Directors
Subscribe now